AbTherx and Spice Biotechnologies Announce Multi-Program Antibody Discovery Collaboration

May 12, 2025 6:00 AM

AbTherx, Inc., a biotechnology company with innovative transgenic technologies that enable and accelerate antibody discovery, today announced a multi-program antibody discovery partnership with Spice Biotechnologies. The partnership will leverage AbTherx's suite of innovative Atlas™ Mouse technologies to deliver antibodies against targets selected by Spice Bio.AbTherx's antibody discovery platform is built on two decades of experience and...

Read more

Alligator Bioscience to Attend ASCO 2025 Annual Meeting

May 12, 2025 2:50 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX) is pleased to announce that data from its OPTIMIZE-1 clinical trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation, titled "Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer," will take place during the Developmental...

Read more

Faron Pharmaceuticals Presents Promising Phase 1/2 Data from BEXMAB Study at MDS 2025 Plenary Session

May 12, 2025 2:20 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - BEXMAB data highlights meaningful clinical benefit, with beneficial immunological and hematological impact in r/r MDSEncouraging survival; Median overall survival 13.4 months in 20 high and very high-risk r/r MDS patients treated with bexmarilimab + azacitidine; 4 patients successfully bridged to hematopoietic stem cell transplant55% patients showed ≥50% reduction in bone marrow; 21% of...

Read more

Jabez Biosciences, Inc. Announced Phase 1 Clinical Trial of JBZ-001 at AACR 2025

May 9, 2025 1:00 PM

Jabez Biosciences, Inc., a pioneering biotechnology company focused on innovative cancer therapies, proudly shared the progress of its Phase 1 clinical trial for JBZ-001 (HOSU-53), a novel dihydroorotate dehydrogenase (DHODH) inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting held April 25-30, 2025, in Chicago, IL. The trial, conducted in collaboration with The Ohio State University Comprehensive Cancer...

Read more

Alligator Bioscience Announces that 85% of the Warrant Programme TO 12 has Been Secured and that the Outstanding Loan has Been Renegotiated

May 9, 2025 10:15 AM

Alligator Bioscience (STO:ATORX)("Alligator Bioscience" or the "Company") hereby announces that the Company has received undertakings corresponding to 85 per cent of the outstanding warrants series TO 12 ("TO 12") (the "Warrant Programme"). The Company has received subscription undertakings from the Company's Chairman of the Board of Directors, CEO and CFO as well as several larger and smaller holders of TO 12, including Roxette Photo SA,...

Read more

Alligator Bioscience Completes Phase 3 GMP Manufacturing of Mitazalimab, Remains on Track for Trial Initiation with Partner

May 9, 2025 3:00 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced the successful completion of the manufacture of the first GMP drug product batch of its lead asset mitazalimab using a new improved commercial-scale manufacturing process. The material is intended for the planned Phase 3 trial in first line metastatic pancreatic cancer. The batch was produced at Thermo Fisher Scientific, a global leader in pharmaceutical manufacturing. This key...

Read more

CB Scientific, Inc. (CBSC) Announces Corporate Name Change to Cardiac Biotech Solutions, Inc.

May 8, 2025 8:00 AM

Cardiac Biotech Solutions, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products, announced today that the Company's name was changed to "Cardiac Biotech Solutions, Inc." effective May 7, 2025, following completion of the review of the Company's application to change its name by the Financial Industry Regulatory Authority (FINRA) and approval of the name...

Read more

Alligator Bioscience Updates Dividend Policy

May 8, 2025 5:00 AM

Alligator Bioscience (STO:ATORX) - Alligator Bioscience AB (publ) today announces an update to its dividend policy following the constitution of Alligator's new Board of Directors on 7 May 2025.The updated dividend policy reads as follows:Alligator will continue to focus on further developing its project portfolio and pursue partnerships for, or the sale of, its projects. Should Alligator receive significant proceeds from such events, the...

Read more

eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST

May 7, 2025 5:20 PM

eXoZymes Inc. (NASDAQ:EXOZ) ["eXoZymes"] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Monday, May 12, 2025 at 5:00 PM Eastern Time to discuss its results for the first quarter of 2025, as well as share more details around the newly formed purpose-built subsidiary, NCTx.Michael Heltzen, CEO of eXoZymes, will lead the call...

Read more

LifeQ and BlueZone Launch Advanced Wearable Health Tech in Mainland China

May 7, 2025 9:00 AM

In a landmark collaboration marking a leap in digital health innovation, LifeQ has partnered with BlueZone to introduce its proprietary biometrics technology platform to mainland China. This initiative brings LifeQ's breakthrough health insights-derived from everyday wearables-to one of the largest and fastest-growing digital health markets in the world.BlueZone is pioneering a next-generation health platform tailored to the distinct needs of...

Read more

Aspira Successfully Completes Application to the OTCQB

May 7, 2025 7:00 AM

Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering the leading tools critical to gynecologic disease diagnostics and disease management, today announced it has successfully completed the process of transitioning to the OTCQB markets exchange. The Company begins trading on the OTCQB marketplace today, May 7, 2025."This is a positive next step for Aspira and our...

Read more

Bulletin from the Annual General Meeting in Alligator Bioscience AB on 7 May 2025

May 7, 2025 5:00 AM

Alligator Bioscience (STO:ATORX) - The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.Today, on 7 May 2025, the annual general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows below.Resolution on adoption of accounts and distribution of the company's resultThe annual general meeting resolved to...

Read more

eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health

May 6, 2025 4:10 PM

Today at the yearly SynBioBeta conference, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced the formation of ‘NCTx, LLC' (NCTx), a purpose-built subsidiary company focused on the development and production of N-trans-caffeoyltyramine - a very rare, plant-derived compound with emerging relevance in the...

Read more

Bulletin from the Annual General Meeting of Vicore Pharma Holding AB (publ)

May 6, 2025 10:35 AM

Vicore Pharma Holding (STO:VICO) - The following resolutions were passed at the annual general meeting (the "AGM") of Vicore Pharma Holding AB (publ) on 6 May 2025.Adoption of income statement and balance sheet for the financial year 2024 and discharge from liabilityThe AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2024 as well as the balance sheet and consolidated balance sheet as of 31...

Read more

Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform

May 6, 2025 9:20 AM

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces it has implemented multiple enhancements to its developing AI platform, which is expected to improve processing and fraud detection and provide a better overall experience. The AI Platform is expected to be a key component of the Company's...

Read more

PharmaNest to Present Five Digital Pathology and AI Communications at EASL 2025, Showcasing Advances in Fibrosis and Inflammation Research

May 6, 2025 9:00 AM

PharmaNest Inc., a leader in high-resolution quantitative digital pathology and artificial intelligence, announced today that it will present five abstracts at the 2025 International Liver Congress (EASL) in Amsterdam, Netherlands, taking place May 7-10. Developed in collaboration with academic and industry leaders, these presentations highlight the capabilities of PharmaNest's FibroNest digital pathology biomarkers in assessing fibrosis and...

Read more

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

May 6, 2025 8:01 AM

Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology released pharmacokinetic and metabolism data from its Phase 1 study of TH104, a buccal film formulation of nalmefene, in healthy subjects. Tharimmune recently highlighted the advancement of TH104 for the proposed indication of temporary prophylaxis against...

Read more

Interim Report January – March 2025

May 6, 2025 2:20 AM

Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for first quarter 2025."As we conclude the first quarter of 2025, I am proud to reflect on Vicore Pharma's focused execution and unwavering commitment to advancing a potentially disease-modifying treatment for IPF. This quarter was a period of operational...

Read more

BioInvent to Participate in Upcoming Investor Conferences

May 5, 2025 9:45 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the Company management team will participate in the following upcoming investor conferences during May and June:Bio€quity Europe 2025 Format: Corporate presentation and one-on-one meetings Date and Time: May 13, 2:45 pm...

Read more

C2Dx Announces Rebrand to Everis Medical, Marking a New Era of Growth

May 5, 2025 9:00 AM

C2Dx, a leading medical device company known for acquiring and revitalizing essential, underserved technologies, is proud to announce its rebrand to Everis. This transformation reflects the company's continued commitment to elevating possibilities in healthcare, expanding its focus, and propelling impactful surgical technologies forward.Founded in 2019 by industry experts, C2Dx was built on the belief that proven medical devices still have...

Read more